Classic diseases revisited

Acne: a review of immunologic and microbiologic factors

Craig G Burkhart, Craig N Burkhart, Paul F Lehmann

Acne vulgaris, the most common cutaneous disorder, is manifested by comedones, papules, pustules, and cysts. The aetiology of acne appears to be multifactorial. The exact mechanism triggering the development of the comedone and the stimuli causing the non-inflamed lesion to become inflamed are poorly understood. The microbiology of acne vulgaris and its immunologic ramifications constitute the major thrust of present research in the elucidation of the pathogenesis of the inflammatory acne lesion.

The microbiology of the pilosebaceous unit involves three coexisting groups of microorganisms: Gram-positive, coagulase-negative cocci (staphylococci and micrococci); anaerobic diphtheroids (Propionibacterium acnes and Propionibacterium granulosum); and lipophilic yeasts (Malassezia species). The microflora of comedones is qualitatively identical to that of the normal sebaceous follicle.

If the microbial flora is significant in the pathogenesis of acne, the most likely organism to blame is \( P \) acnes, a strict anaerobe that has been shown serologically and biochemically to be identical to \( Corynebacterium \\textit{parvum}, \) a potent stimulator of the reticuloendothelial system. This organism has been used as an immunostimulatory adjunct in chemotherapy of numerous tumours.\(^1\) \( P \) acnes is overwhelmingly the predominant microorganism in the normal pilosebaceous follicle, as well as in the acne state, and has been divided into two serotypes and five biotypes. Up to \( 10^7 \) viable \( P \) acnes have been isolated from a single sebaceous unit. \( P \) acnes is not pathogenic by normal standards because there is no correlation between the number of bacteria and the severity and type of acne. Nevertheless, \( P \) acnes appears to be the target of oral and topical antibiotic usage, and the reduction in numbers of \( P \) acnes is a just parameter of therapeutic effectiveness of antibiotics.

\( P \) acnes secretes several extracellular products that may be significant in the aetiology of acne. These include hyaluronidase, proteases, lipases, and chemotactic factors for neutrophils, lymphocytes, and macrophages. The microbiology of the pilosebaceous unit is likely to play a major role in the amount of exoenzymes that are produced by the organism because in vitro studies demonstrate that their production is altered by factors such as pH and oxygen tension.

The current interest in \( P \) acnes revolves around whether its immunopotentiating properties are pertinent in the pathogenesis of acne. Specifically, there is reason to believe that \( P \) acnes may be a direct instigator of inflammation in acne via its interaction with antibody and complement, its chemotactic properties, and via cell-mediated immunity.

Humoral immunity

Patients with inflammatory acne develop an immune response to \( P \) acnes. Circulating immune complexes have been reported to be elevated in some acne patients. The degree of elevation has been correlated with the severity of acne inflammation.\(^7\) \(^8\) Additionally, complement-fixing antibody titres to \( P \) acnes are
elevated, and the titres parallel the severity of the inflammation. In minimal acne, these antibody titres are rarely greater than the levels found for most adults. The antibodies to *P acnes* have not been characterised fully, although they are reported to be largely of the IgG class. Total IgG levels are slightly increased in some patients with severe acne, which may reflect an enhanced B-cell activity, although they may be lower than normal in others. Titres of IgG3 have been demonstrated to be higher in severe cases. We have shown the dominant antigen to be in the soluble extract of *P acnes* and to have a carbohydrate component.

The elevated antibody response to *P acnes* appears to be specific because antibody titres for *Staphylococcus epidermidis* are not raised in acne. At least four major antigenic components have been detected on analysis of the extracellular supernatant fluid from dialysed *P acnes* cultures. Variations in the antigenic composition of *P acnes* may account for some of the differences in antibody patterns that are seen in individuals.

Immunofluorescence studies have revealed *P acnes* antigens in the dermis surrounding the pilosebaceous units in acne patients. In contrast, the antigens are confined totally within the follicular walls in normal skin.

**Cell-mediated immunity**

Cell-mediated immunity could contribute to the development of inflammation in acne; however, this role is far from having been proven. Skin tests, made with common recall antigens such as trichophytin, mumps, or purified protein derivative, have demonstrated that patients with severe acne may have a depressed or absent reactivity. Such deficiencies are not matched by defects in mitogen-induced lymphocyte blastogenesis *in vitro* where the responses of patients' lymphocytes to phytohaemagglutinin occur at normal levels. However, acne patients have a depressed number of E-rosette-forming cells, indicating that some form of T-cell deficiency may be present.

Specific responses to antigens prepared from *P acnes* have been studied. Various types of skin test responses are reported, including both the classic immediate-type and delayed-type hypersensitivity reactions, as well as ill-defined erythematous reaction that disappears before 48 hours postinjection. The latter may be caused by the inflammation brought about from the activation of complement by antibody–antigen complexes or by materials in the antigen preparation.

The type of skin test response shown by acne patients appears to depend, at least in part, on the nature of the antigen preparation, the dosage used for the skin test, and possibly on the isolate of *P acnes* from which the antigen is prepared. Thus, Puhvel et al reported immediate hypersensitivity reactions as being characteristic of acne patients who had been skin-tested with *P acnes* antigen prepared from disrupted cells or from a dialyzed culture filtrate. Less than half of their patients developed a delayed reaction that remained visible at 48 hours. In contrast, Kersey et al used heat-killed *P acnes* as antigen and reported strong delayed responses in the patients, the strongest response being found for the most severe acne cases. It is a distinct possibility that the strong immediate skin test response reported by Puhvel et al prevented subsequent development of a delayed response, a phenomenon that was described over 40 years ago for the trichophytin skin test.

Although the results from specific skin tests are still somewhat confusing, it is generally accepted that the *in vitro* tests for lymphocyte transformation and for production of the lymphokine leukocyte migration inhibitory factor show that acne patients' lymphocytes develop a hyperreactivity to *P acnes* antigens. Thus, the stage is set for a contribution by cell-mediated immune responses to the inflammation in acne.

**Complement activation**

The activation of complement leads to the release of inflammatory mediators, causing mast cell degranulation, leukocyte chemotaxis, and lysosomal enzyme release. Both comedonal contents and *P acnes* have been shown to activate complement via both the classic and the alternate pathways. Immunofluorescence of skin specimens from acne patients have revealed the presence of C3 deposits in the dermal vessel walls. On occasion, immunoglobulins are seen in addition to complement, and this provides suggestive evidence of the formation of immune complexes around the acne lesion. Thus, complement fixation may play a major role in inducing the inflammation seen in the acne lesion.
Cytotoxins and neutrophil function

Early acne lesions reveal polymorphonuclear leukocytes accumulating at the periphery of pilosebaceous units and later migrating within the hair follicle. The production of cytotoxins, which stimulate chemotactic activity independently of complement, has been investigated in acne. Materials produced by *P. acnes* and by other comedonal bacteria grown *in vitro* can stimulate neutrophil chemotaxis. The fraction of *P. acnes* with chemotactic activity appears to consist of predominantly low molecular weight material. However, crude comedonal extracts are reported to be toxic for neutrophils, with the free fatty acids appearing to be responsible for the cytotoxicity. The crude comedonal extract is, however, a chemoattractant for monocytes, even though toxicity is reported. Thus, the importance of cytotoxin production for acne lesion formation is unclear at present. Indeed, the activation of complement by both comedonal material and *P. acnes* may be of greater importance for inducing neutrophil chemotaxis in acne.

There have been relatively few studies on neutrophil function in acne patients. Enhanced chemotactic and random migratory activities have been reported by some, but others find activity at normal levels. In general, phagocytic activities appear normal for bacteria such as *Staphylococcus aureus*. Lee and Shalita have indicated that some patients with severe acne have a marked depression in their neutrophil chemotaxis, while in other patients chemotaxis is increased. In this latter group, they reported finding a defect in phagocytosis that was specific for *P. acnes*. Further research should clarify the role of abnormal neutrophil functions in the pathogenesis of acne.

Treatment considerations

Acne therapy must address the aetiological factors involved in acne pathogenesis. These treatment considerations include correcting the altered pattern of follicular keratinization, reducing sebaceous gland production, diminishing the *P. acnes* population in the follicle and inhibiting its production of extracellular inflammatory products, and producing an anti-inflammatory effect. Coexistent with the immune theories of the pathogenesis of acne, there have been several modes of therapy applied to patients with severe acne. Possibly because of the presence of isoretinoxin or the venerable microcomedonal theory of acne, few clinical trials have materialised since the early 1980s.

Intralesional and oral steroids are occasionally used to reduce inflammation in severe cases of acne. Cimetidine, which affects cell-mediated immunity as well as being anti-androgenic, has had conflicting results as to its therapeutic efficacy. Levamisole restored the impaired T-cell function in acne patients as well as bringing about some clinical improvement. A polyvalent *P. acnes* vaccine has been reported to have had modest success, as has transfer factor. Finally, it has been suggested that tetracycline, which becomes concentrated in inflamed lesions and has been the mainstay of acne treatment for two decades, could act by inhibiting neutrophil chemotaxis rather than its antibacterial actions.

*P. acnes* plays a central role in acne pathogenesis. Not only does this anaerobic bacterium produce lipases, proteases, and other extracellular enzymes, it also secretes chemotactic factors attracting polymorphonuclear leukocytes, lymphocytes, and macrophages. The inflammatory response initiated by these extracellular products stimulates the classical and alternative complement pathways and other immune responses. Thus, *P. acnes* directly contributes to the existence of acne via its effects on humoral and cell-mediated immunity, complement activation, and cytotoxin production. Further studies on the immunological factors involved in acne pathogenesis are warranted.


Acne: a review of immunologic and microbiologic factors

Craig G Burkhart, Craig N Burkhart and Paul F Lehmann

Postgrad Med J 1999 75: 328-331
doi: 10.1136/pgmj.75.884.328

Updated information and services can be found at:
http://pmj.bmj.com/content/75/884/328

These include:

References
This article cites 28 articles, 3 of which you can access for free at:
http://pmj.bmj.com/content/75/884/328#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/